Management of Dogs and Cats With Cognitive Dysfunction
Lynne Seibert, DVM, MS, PhD, DACVB
Veterinary Behavior Consultants, Roswell, Georgia
Behavior changes in older patients can indicate underlying medical issues, diminishing sensory capacities, age-related cognitive decline, a primary behavioral disorder, or a combination of these. Behavior problems can cause significant suffering for the patient, may challenge the caregiver’s ability to care for the pet, and may prompt the caregiver to relinquish or euthanize the pet. Early diagnosis and treatment are critical.
Cognitive functions include the mental processes of perception, awareness, learning, and memory, which allow an individual to acquire information about the environment and decide how to act. Cognitive dysfunction syndrome (CDS) is a neurobehavioral disorder affecting geriatric dogs and cats that is characterized by an age-related decline in cognitive abilities sufficient to affect functioning, with behavior changes that are not attributable to other medical conditions. The prevalence of CDS in dogs is extremely high, ranging from 28% in 11- to 12-year-old dogs to 68% in 15- to 16-year-old dogs.1 The prevalence of CDS in cats was 36% in a population of 11- to 21-year-old cats. The incidence of behavior changes increased with advancing age: Fifty percent of cats aged 15 years and older showed behavior changes versus 28% of cats aged 11 to 14 years. The most common behaviors seen in the 11- to 14-year-old age group were alterations in social interactions. In cats aged 15 years and older, the most common signs were aimless activity and excess vocalization.2
CDS is underdiagnosed because caregivers may assume behavior changes are a result of normal aging, and veterinarians may not recognize the signs. In a large cross-sectional study of dogs aged 8 to almost 20 years, researchers investigated the prevalence of canine cognitive dysfunction, along with the rate of veterinary diagnosis.3 On the basis of owner questionnaire data, the prevalence rate of CDS was estimated to be 14.2%. However, only 1.9% of cases were diagnosed by a veterinarian. The prevalence of CDS exponentially increased with age but did not differ by breed.3
Cognitive dysfunction syndrome (CDS) is underdiagnosed because caregivers may assume behavior changes are a result of normal aging, and veterinarians may not recognize the signs.
CDS is an antemortem diagnosis of exclusion. Caregiver interviews using questionnaires (Table 1) are an important tool for assessing geriatric patients. It is important to exclude other systemic diseases that could account for clinical signs before reaching a diagnosis.
Aging affects all organ systems, and changes in many systems can present with behavioral signs (Box 1). Human patients with Alzheimer’s disease often exhibit movement disorders, including restlessness, impaired gait, and tremors. Concurrent behavioral and neurologic signs in aging canine patients have also been documented. In a study of 21 dogs older than 7 years, those with CDS were twice as likely to show neurologic deficits as dogs without CDS.4
The medical evaluation should include a thorough physical and neurologic examination, orthopedic examination, pain assessment, and appropriate diagnostic testing, including complete blood profile, biochemistry panel, urinalysis, systemic blood pressure measurement, and additional testing as indicated by the clinical signs (eg, radiography, ultrasonography, endocrine tests). Magnetic resonance imaging and cerebral spinal fluid analysis are useful for assessing the presence of certain intracranial lesions that might mimic CDS, such as inflammatory, infectious, or neoplastic diseases.
Senior-pet checklists typically include questions about disorientation, social interactions with humans and other animals, sleep–wake cycle changes, house soiling, and changes in activity levels. Locomotor and exploratory behaviors vary as a function of age and cognitive status. One study administered two tests to 85 dogs varying in age and cognitive status to explore their locomotor and exploratory behaviors.5 Cognitively impaired older dogs had higher locomotor activity and spent more time in aimless activity than young dogs (younger than 9 years); the more severe the cognitive impairment, the higher both of these measures were. Older dogs also demonstrated an age-dependent decline in exploratory behavior.5
Changes in social interactions with owners and other animals are frequently observed in dogs with CDS. Another pair of tests was administered to assess social responsiveness in dogs of varying ages and cognitive status.6 Social responsiveness was primarily affected by age but was also influenced by severity of cognitive impairment. Young dogs engaged in more physical contact with humans and more vocalizations in response to social isolation, but aged dogs spent more time near a mirror, suggesting a deficit in habituation to the reflection of a dog image.6
To investigate the sleep–wake patterns in aged dogs, radiotelemetry monitoring has been conducted. In elderly dogs, the sleep–wake patterns were dramatically altered.7 The changes were characterized by an increase in the total amount of time spent in slow-wave sleep during the daytime and an increase in time spent awake during the night.
Rating scales are essential tools for CDS diagnosis and evaluation of the efficacy of therapeutic strategies. An ideal rating scale is simple and quick to administer, statistically validated, and applicable to all stages of the disease. The validity and reliability of scales should be evaluated before use.
The Canine Dementia Scale, or CADES, is a statistically validated, highly sensitive rating scale for canine CDS. The scale contains 17 nonredundant items, distributed across 4 relevant domains: (1) spatial orientation, (2) social interactions, (3) sleep–wake cycles, and (4) house soiling. In a study,8 dogs with mild cognitive impairment frequently had impaired social interactions. Most dogs with moderate cognitive dysfunction had abnormal social interactions and sleep–wake cycles. For severe cognitive dysfunction, most dogs displayed impairment in all 4 domains.8
The brain consumes 20% of the body’s total oxygen. Its high percentage of polyunsaturated fatty acids and lower levels of endogenous antioxidant activity make it very susceptible to oxidative damage. Cellular metabolic processes release reactive oxygen species, which can lead to oxidative damage to proteins, lipids, DNA, and RNA, resulting in neuronal death. Normally, the activity of endogenous antioxidants balances the production of toxic free radicals. However, protective mechanisms begin to fail with age. Oxidative damage is associated with cognitive decline in dogs. An increase in oxidative end products in the brain of aged dogs correlates with more severe behavioral changes.9
The brains of older mammals show several anatomic and physiologic changes. These include a reduction in overall brain mass (including atrophy of cerebral cortex and basal ganglia), a reduction in the number of neurons, generalized gliosis, degeneration of white matter, demyelination, neuroaxonal degeneration, increases in ventricular size, meningeal fibrosis and calcification, and the presence of β-amyloid (Aβ) plaques. Functional changes include depletion of catecholamine neurotransmitters (norepinephrine, serotonin, and dopamine), a decline in the cholinergic system, an increase in monoamine oxidase B (MAO-B) activity, and a reduction of endogenous antioxidants.10
Several histopathologic similarities exist between human brains affected by Alzheimer’s disease and dog brains affected by CDS. The brains of 20 geriatric dogs aged 8 to 18 years were compared with the brains of 10 younger dogs; age-related pathologic changes of the meninges, choroid plexus, neurons, and glial cells were similar to changes seen in human brains.11
In both diseases, the aged brain develops an abnormal Aβ deposition in brain parenchyma and the walls of the cerebral blood vessels. Aβ is a protein produced by the degradation of amyloid precursor protein. The prefrontal cortex is the first area affected, followed by the temporal cortex, the hippocampus, and the occipital cortex. Regardless of position, the amount and extent of Aβ deposits correlate with the severity of cognitive impairment.12
Geriatric patients should receive regular examinations to address nutritional needs, obesity management, pain control, and physical and mental changes. Effective management of CDS may involve environmental and behavioral interventions, dietary modifications and nutritional supplements, pharmaceutical treatments, and complementary therapies.
Enrichment and Environmental Management
The environment may need to be modified to accommodate the aging pet’s needs and improve comfort. Resources need to be easily accessible. Litterboxes may need to be placed in additional locations. Older dogs may require more opportunities for elimination, either outdoors or in an indoor elimination area. If nocturnal waking is a problem, owners should increase the pet’s daytime exercise and reduce disturbances in the evening. Geriatric pets may be less tolerant of children and other household pets and should be provided with protected resting areas. Older pets may also be less tolerant of environmental changes and may require behavioral assistance if changes induce anxiety-related problems.
Behavioral modification is similar to approaches used for younger pets, but with some limitations or constraints. Padded surfaces for sitting and traction for movement may help. If the pet is in pain, “stand” or “look” commands may replace frequent “sit” or “down” cues. Owners may need to adjust behavior signals used in training if sensory dysfunction is significant, including tactile cues or hand signals. More powerful motivators for learning may be needed, including the use of high-value food rewards.
Maintaining a regular routine can reduce anxiety, and providing regular mental stimulation and enrichment will help maintain cognitive functioning.
Diets containing antioxidants, mitochondrial cofactors, phosphatidylserine, and omega-3 fatty acids have proven beneficial for geriatric patients. Dietary treatment of CDS has focused primarily on reducing the deleterious effects of toxic free radicals. Cognitive improvements have been documented in older dogs fed a therapeutic antioxidant-rich diet containing flaxseed, carrots, spinach, citrus pulp, tomato pomace, grape pomace, α-lipoic acid, vitamin E, vitamin C, vitamin B12, pyridoxine, choline, l-lysine, l-tryptophan, l-carnitine, and β-carotene (Hill’s Prescription Diet b/d Canine; hillspet.com).13
The effects of the fortified diet with and without behavioral enrichment have been evaluated.14,15 Behavioral enrichment consisted of additional training (30 min/d, 5 days/wk), an enriched environment (housing with a kennel mate and weekly rotation of play toys), and physical exercise (two 20-minute outdoor walks/wk). The cognitive scores of the dogs fed a fortified diet and receiving behavioral enrichment were superior to those in all the other groups. Neurobiologic studies showed reduced oxidative damage and increased endogenous antioxidant activity in antioxidant-fed dogs, particularly among the dogs that received behavioral enrichment.14,15
Although no equivalent feline diet is available, Hill’s Prescription Diet Feline j/d, which is designed for cats with osteoarthritis, is supplemented with antioxidants and essential fatty acids. This diet may be useful for cats with signs of cognitive decline.
Glucose is the main energy source of neurons. However, glucose metabolism is reduced with aging. Other energy sources, such as ketone bodies, may be needed to maintain neuronal metabolism. Dietary medium-chain triglycerides (MCTs) can increase the levels of ketones in the blood, which can be used as an alternate energy source for cerebral functioning. Fatty acids derived from MCTs could provide up to 20% of the brain’s energy requirements.16 Long-term supplementation with MCTs has improved cognitive function in aged dogs (Purina One Vibrant Maturity 7+ Senior Formula, Purina ProPlan Veterinary Diet NC NeuroCare; purina.com). Dogs given a diet supplemented with 5.5% MCT for 8 months showed significantly better performance on cognitive tasks than control dogs.17 Diets supplemented with this type of lipid also reduce levels of Aβ deposits and improve mitochondrial function.18
Phosphatidylserine is a natural phospholipid in cell membranes and is found at high concentrations in the brain and at synapses. It facilitates membrane-dependent neuronal processes; enhances acetylcholine release; inhibits loss of muscarinic receptors; activates synthesis and release of dopamine; and may improve memory, learning, and social behavior in dogs and cats.19
A placebo-controlled trial evaluated a supplement containing essential fatty acids (docosahexaenoic acid and eicosapentaenoic acid), N-acetylcysteine (a primary precursor to glutathione), α-lipoic acid, vitamins C and E, l-carnitine, selenium, coenzyme Q10, and phosphatidylserine.20 The treated group showed significantly more improvement than the placebo group with regard to disorientation, changes in social interactions, and house-soiling behavior within 21 days of starting treatment.
A supplement containing 25 mg phosphatidylserine, 50 mg standardized Ginkgo biloba extract, 33.5 mg α-tocopherol, and 20.5 mg pyridoxine per capsule was administered to 8 dogs at 1 capsule per 5 kg body weight in an open-label pilot study (Senilife; ceva.com).21 Dogs treated with this supplement showed marked improvement of CDS-related signs.
Dysregulation of intracellular calcium is associated with increased age and may be linked to CDS in dogs. Apoaequorin is a calcium-buffering protein with neuroprotective effects (Neutricks; quincybioscience.com). Aged beagles given apoaequorin at doses of 2.5 mg or 5 mg were better able to complete discrimination learning and attention tasks than the placebo group.22 Dogs treated with 10 mg apoaequorin showed superior performance on cognitive tasks compared with dogs receiving 1 mg/kg selegiline.
S-Adenosyl-l-methionine (SAMe) is an endogenous molecule synthesized by the liver and other cells throughout body and formed from the amino acid methionine. SAMe is essential for the major biochemical pathways and metabolic reactions in the liver. Exogenous SAMe increases endogenous production of the antioxidant glutathione, resulting in increased serotonin turnover and increased dopamine and norepinephrine levels.
Pure SAMe is unstable and highly reactive, so commercially available oral forms of SAMe are salts (Novifit [virbac.com]; Denosyl, Nutramax [nutramaxlabs.com]). Oral bioavailability depends on the salt used. The presence of food in the gut can significantly decrease absorption, so SAMe should be administered on an empty stomach, 1 hour before feeding.
Oral SAMe tosylate supplementation (Novifit tablets) was evaluated as a dietary aid for the management of age-related cognitive decline in dogs.23 Dogs were administered placebo or 18 mg/kg SAMe tosylate for 2 months, with no associated behavior modification. SAMe-treated dogs showed significantly greater improvement in activity and awareness at 4 weeks and 8 weeks compared with placebo-treated dogs.23
Selegiline hydrochloride (Anipryl; zoetis.com) is approved for the control of clinical signs associated with canine CDS. Selegiline is a selective and irreversible inhibitor of the enzyme MAO-B. In the central nervous system, MAO-B is responsible for catabolism of catecholamines, dopamine, and, to a lesser extent, norepinephrine and serotonin. Inhibition of MAO-B results in increased levels of phenylethylamine, increased dopamine release, decreased uptake of dopamine and other monoamine neurotransmitters, antioxidant activity, and decreased free radical formation.
Clinical trials showed selegiline hydrochloride to be effective in controlling clinical signs associated with CDS after 4 weeks of treatment.24 Dogs receiving selegiline hydrochloride showed significant improvement when compared with placebo-treated controls in sleeping patterns, housetraining, and activity level.
The approved dose of selegiline hydrochloride for dogs is 0.5 to 1.0 mg/kg q24h, to be given in the morning, dosed to the nearest whole tablet, with adjustments based on response and tolerance. The onset of action varies (4 to 12 weeks), and improvement may increase with extended use. Selegiline hydrochloride has been used off-label in cats with cognitive dysfunction at 0.25 to 0.5 mg/kg q24h.
Possible side effects include restlessness or agitation, vomiting, disorientation, or diarrhea. Selegiline should not be used in combination with other MAO inhibitors, including amitraz, opioids, α2 agonists, phenylpropanolamine, tricyclic antidepressants, selective serotonin reuptake inhibitors, or any other serotonergic agents (including trazodone, tramadol, and buspirone). At least 14 days should elapse between discontinuation of selegiline and initiation of treatment with a tricyclic antidepressant or selective serotonin reuptake inhibitor. Because of the long half-life of fluoxetine and its active metabolites, at least 6 weeks should elapse between discontinuation of fluoxetine and initiation of treatment with selegiline.
N-Methyl-d-Aspartate Receptor Antagonists
Memantine binds to N-methyl-d-aspartate receptors in the brain and blocks the activity of glutamate. Excessive glutaminergic activity resulting in neurotoxicity is suspected in the pathology of dementia. Memantine is used in the treatment of moderate to severe Alzheimer’s disease. It has been used in dogs to treat compulsive behaviors, at a dose of 0.3 to 1.0 mg/kg q12h.25
Older pets often have anxiety-related conditions. Therefore, anxiolytic agents may also be indicated, including selective serotonin reuptake inhibitors, tricyclic antidepressants, azapirones, γ-aminobutyric acid agonists, or benzodiazepines, with attention to potential drug interactions.
Complementary therapies may include compression garments (Thundershirt [thundershirt.com], Anxiety Wrap [anxietywrap.com]), pheromones, aromatherapy, herbal supplements, acupuncture, acupressure, massage, or physical therapy.
Senior dogs and cats should be evaluated for signs of cognitive impairment by using the diagnostic tools available, and treatment should be initiated as early as possible. Treatment options include pharmaceutical agents, dietary therapy, nutritional supplements, and behavioral enrichment. With thorough senior pet evaluations and clear client communication, veterinarians can help older pets live happier, healthier, more comfortable lives.
- Neilson JC, Hart BL, Cliff KD, Ruehl WW. Prevalence of behavioral changes associated with age-related cognitive impairment in dogs. JAVMA 2001;218(11):1787-1791.
- Moffat KS, Landsberg GM. An investigation of the prevalence of clinical signs of cognitive dysfunction syndrome (CDS) in cats. JAAHA 2003;39(5):512.
- Salvin HE, McGreevy PD, Sachdev PS, Valenzuela MJ. Under diagnosis of canine cognitive dysfunction: a cross-sectional survey of older companion dogs. Vet J 2010;184(3):277-281.
- Golini L, Colangeli R, Tranquillo V, Mariscoli M. Association between neurologic and cognitive dysfunction signs in a sample of aging dogs. J Vet Behav 2009;4(1):25-30.
- Rosado B, González-Martínez A, Pesini P, et al. Effect of age and severity of cognitive dysfunction on spontaneous activity in pet dogs—part 1: locomotor and exploratory behavior. Vet J 2012;194(2):189-195.
- Rosado B, González-Martínez A, Pesini P, et al. Effect of age and severity of cognitive dysfunction on spontaneous activity in pet dogs—part 2: social responsiveness. Vet J 2012;194(2):196-201.
- Takeuchi T, Harada E. Age-related changes in sleep-wake rhythm in dog. Behav Brain Res 2002;136(1):193-199.
- Madaria A, Farbakova J, Katina S, et al. Assessment of severity and progression of canine cognitive dysfunction syndrome using the Canine Dementia Scale (CADES). Appl Anim Behav Sci 2015;171:138-145.
- Skoumalova A, Rofina J, Schwippelova Z, et al. The role of free radicals in canine counterpart of senile dementia of the Alzheimer type. Exp Gerontol 2003;38(6):711-719.
- Landsberg GL, Araujo JA. Behavior problems in geriatric pets. Vet Clin North Am Small Anim Pract 2005;35(3):675-698.
- Borras D, Ferrer I, Pumarola M. Age related changes in the brain of the dog. Vet Pathol 1999;36(3):202-211.
- Schmidt F, Boltze J, Jager C, et al. Detection and quantification of β-amyloid, pyroglutamil Aβ, and tau in aged canines. J Neuropathol Exp Neurol 2015;74(9):912-923.
- Cotman CW, Head E, Muggenburg BA, et al. Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol Aging 2002;23(5):809-818.
- Milgram NW, Head E, Zicker SC, et al. Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. Neurobiol Aging 2005;26(1):77-90.
- Opii WO, Joshi G, Head E, et al. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer’s disease. Neurobiol Aging 2008;29(1):51-70.
- Pan Y. Enhancing brain function in senior dogs: a new nutritional approach. Topics Compan Anim Med 2011;26(1):10-16.
- Pan Y, Larson, B, Araujo JA, et al. Dietary supplementation with medium-chain TAG has long-lasting cognition-enhancing effects in aged dogs. Br J Nutrition 2010;103:1746-1754.
- Taha AY, Henderson ST, Burnham WM. Dietary enrichment with medium chain triglycerides (AC-1203) elevates polyunsaturated fatty acids in the parietal cortex of aged dogs; implications for treating age-related cognitive decline. Neurochem Res 2009;34(9):1619-1625.
- Osella MC, Re G, Badino P, et al. Phosphatidylserine (PS) as a potential nutraceutical for canine brain aging: a review. J Vet Behav Clin Appl Res 2008;3(2):41-51.
- Heath SE, Barabas S, Craze PG. Nutritional supplementation in cases of canine cognitive dysfunction—a clinical trial. Appl Anim Behav Sci 2007;105(4):274-283.
- Osella MC, Re G, Odore R, et al. Canine cognitive dysfunction syndrome: prevalence, clinical signs and treatment with a neuroprotective nutraceutical. Appl Anim Behav Sci 2007;105(4):297-310.
- Milgram NW, Landsberg G, Merrick D, Underwood MY. A novel mechanism for cognitive enhancement in aged dogs with the use of a calcium-buffering protein. J Vet Behav 2015;10(3):217-222.
- Rème CA, Dramard V, Kern L, et al. Effect of S-adenosylmethionine tablets on the reduction of age-related mental decline in dogs: a double-blinded, placebo-controlled trial. Vet Therap Res Appl Vet Med 2008;9(2):69-82.
- Milgram NW, Ivy GO, Head E, et al. The effect of L-deprenyl on behavior, cognitive function, and biogenic amines in the dog. Neurochem Res 1993;18(12):1211-1219.
- Schneider BM, Dodman NH, Maranda L. Use of memantine in treatment of canine compulsive disorders. J Vet Behav 2009;4(3):118-126.